|
CollPlant Biotechnologies, a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, announced that the Korean Patent Office has allowed a patent application covering key aspects of the company's photocurable dermal filler technology currently under development for the aesthetic market.
The allowed patent application covers a polymerizable solution and its use in tissue augmentation. The composition is injected into a sub-epidermal tissue space and subsequently polymerized in situ using external light activation. This invention underpins CollPlant's proprietary photocuring platform for dermal fillers.
"This patent allowance represents another important milestone in executing our strategy to expand the clinical and commercial applications of our rhCollagen platform into high-value aesthetic markets," said Yehiel Tal, chief executive officer of CollPlant. "South Korea is a strategically important market in aesthetic medicine, and strengthening our intellectual property position in this region further enhances the long-term value of our technology."
Tal added, "Beyond skin lifting, our photocurable rhCollagen-based filler platform was designed to support structural tissue restoration. Upon light activation, the material forms a supportive scaffold intended to enhance long-term contour stability. The technology is designed not only to restore facial contours but also to provide a regenerative matrix that may promote tissue integration and durable structural improvement. With patent protection extending through 2039, we believe this innovation positions us to compete effectively, upon completion of development, in a global injectable soft-tissue filler market currently estimated to exceed $6 billion and continuing to grow."
The polymerizable formulation comprises chemically modified rhCollagen together with additional constituents, including a hyaluronic acid-based filler component. The solution is engineered to exhibit viscosity suitable for extrusion through a surgical needle of at least 27-gauge at the temperature of use, while enabling post-injection contour modulation before, during or after light-induced curing.
The Korean patent allowance follows the recent grant of a Japanese patent covering, among other things, a photocurable dermal filler kit and related polymerizable compositions comprising chemically modified rhCollagen for use in tissue augmentation. These compositions are introduced into a sub-epidermal tissue space and induced to polymerize upon light activation. CollPlant's photocuring technology is further protected by granted patents in the United States, Europe, China, Brazil, Australia, and Israel, with additional applications pending in other territories.
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
|